Mobile website
Clinical Research
Clinical significance of plasma lysophosphatidic acid in pancreatic carcinoma patients
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective:To observe the levels of plasma lysophosphatidic acid (LPA) in patients with pancreatic carcinoma, and to evaluate its clinical potential of diagnosis. Methods: Plasma LPA and serum CA19-9, AFP and CEA levels were measured in 50 patients with pancreatic carcinoma and 32 patients with benign pancreatic lesions hospitalized in Nanjing First Hospital during June of 2006 and October of 2010, and 36 healthy donors by phosphate determination method. Immunohistochemistry (IHC) was used to determine the expression of LPA2 receptor both in surgically resected pancreatic carcinomas and adjacent non tumor tissues. The correlation between LPA levels with clinical pathological features of pancreatic carcinoma patients was analyzed. Results: Plasma LPA concentration was significantly higher in pancreatic carcinoma patients than in patients with benign lesions and controls (\[4.10±2.03\] vs \[328±1.26\], \[2.27±1.02\] μmol/L, P＜0.05). Plasma LPA concentration was correlated with serum CA19-9 level (r=0.9070, P＜0.01) in patients with pancreatic carcinoma. The positive rate of LPA2 receptor in pancreatic carcinoma tissues was significantly higher than that in adjacent non tumor tissues (88% vs 4%, P＜0.05). Higher plasma LPA level showed a significant correlation with invasion and metastasis of pancreatic carcinoma. Conclusion: Plasma LPA level might be a potential indicator of the diagnosis and prognosis of pancreatic carcinoma.
Keywords:
Project Supported:
Project supported by the Scientific Education “Xinwei Project” of Health Bureau of Jiangsu Province (Jiangsu Health Scientific Education〔2011〕No.15), and the Key Science and Technology Development Program of Medicine of Nanjing, China (No. ZKX09007)
Clc Number:
